Business
iNtRON Seeks a Strategic Partner to Explore the Promising Market for MRSA Decolonization
iNtRON Biotechnology, Inc., a biotechnology company focused on developing innovative endolysin-based new biological drug for superbugs and unmet medical needs, today announced the strategic initiative aimed at expanding the clinical applications of SAL200 and seeking a strategic partnership to target the prevention of surgical site infections (SSIs) by nasal MRSA decolonization.
About this update from Intron Biotechnology, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Aiming to Provide a Novel Solution Against Post-Operative MRSA Infections ","length":73,"tagName":"p"}]},{"val":[{"type":"text","content":"Demonstrated its Efficacy and Safety through previous Clinical Trials ","length":69,"tagName":"p"}]},{"val":[{"type":"text","content":"Company seeks global partners to co-develop toward Commercialization","length":68,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":210,"olType":false},{"type":"text","content":"SEOUL, South Korea and BOSTON, May 13, 2025 /PRNewswire/ -- iNtRON Biotechnology, Inc., a biotechnology company focused on developing innovative endolysin-based new biological drug for superbugs and unmet medical needs, today announced the strategic initiative aimed at expanding the clinical applications of SAL200 and seeking a strategic partnership to target the prevention of surgical site infections (SSIs) by nasal MRSA decolonization.","length":441,"tagName":"p"},{"type":"text","content":"Methicillin-resistant Staphylococcus aureus (MRSA) remains one of the most dangerous superbugs worldwide, with rising infection rates in both hospital and community settings. Even in sterile operating environments, MRSA-related SSIs frequently originate from the patient's own nasal or skin, potentially leading to extended hospital stays, increased treatment costs, and in severe cases, serious systemic infections such as sepsis, osteomyelitis, or endocarditis.","length":467,"tagName":"p"},{"type":"text","content":"High-risk surgical patients including those undergoing implant or cardiac surgeries, or those with compromised immune systems face significantly elevated risks of MRSA infections. Although mupirocin-based nasal ointments have been used as a standard of care product for the prevention of SSI, resistance rates are continuously increasing, leaving clinicians with few effective solution.","length":386,"tagName":"p"},{"type":"text","content":"As an intravenous injection drug for infective endocarditis and bacteremia, SAL200 has already demonstrated a strong safety profile through Phase 1a/1b and Phase 2a clinical trials. Encouraged by recent feedback from key clinical experts, iNtRON is now pursuing an additional indication for SAL200 as a pre-operative MRSA nasal decolonization solution.","length":352,"tagName":"p"},{"type":"text","content":"Acco...